The assets of Second Sight Medical (NSDQ:EYES) are going up for auction on June 25.
The developer and manufacturer of implantable visual prosthetics for blind individuals created the only FDA-approved implantable visual prosthetic treatment for severe retinitis pigmentosa. The company said in March that it was winding down its operations amid the financial shock of the COVID-19 pandemic. In April, Second Sight said it took steps to reduce overhead and conserve liquidity ahead of potential partnering, acquiring, or combining with businesses, just days before pricing a $6.8 million offering of its common stock, which closed in May.
Get the full story on our sister site, Medical Design & Outsourcing.